Cases & Deals

  • Home
  • Practices
  • Neurocrine Biosciences expands patent portfolio related to use of INGREZZA (valbenazine) in treatment of abnormal movement disorders

Share

Neurocrine Biosciences expands patent portfolio related to use of INGREZZA (valbenazine) in treatment of abnormal movement disorders

February 2018

Clients Neurocrine Biosciences, Inc.

Jones Day represents Neurocrine Biosciences, Inc. in prosecution of patent portfolio directed to use of INGREZZA (valbenazine) in treatment of abnormal movement disorders, including tardive dyskenisia and Tourette’s syndrome.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.